Novartis Ag ADR (NY: NVS )
99.27 +0.36 (+0.36%) Streaming Delayed Price Updated: 3:18 PM EDT, Jun 5, 2023 Add to My Watchlist
All News about Novartis Ag ADR
Looking At Novartis's Recent Unusual Options Activity
June 01, 2023
Smokeless Tobacco Treatment Market to See Booming Growth : Novartis, Pfizer, Johnson & Johnson, Cambrex
May 26, 2023
Smokeless Tobacco TreatmentÂ Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies),...
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Why Novartis Stock Is Trading Higher Today
April 25, 2023
Earnings Preview: Novartis
April 24, 2023
Oral Cancer Treatment Market Projected to Show Strong Growth : Bristol-Myers Squibb, Qilu Pharmaceutical, Novartis
May 15, 2023
Get Oral Cancer Treatment Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis.
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
May 09, 2023
Stay up-to-date with AI for Pharma and Biotech Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Topics Artificial Intelligence
Exposures Artificial Intelligence
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
April 25, 2023
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following